Analysts' ratings for Ardelyx ARDX over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Ardelyx, revealing an average target of $14.5, a high estimate of $15.00, and a low estimate of $14.00. Marking an increase of 3.57%, the current average surpasses the previous average price target of $14.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Ardelyx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Laura Chico | Wedbush | Maintains | Outperform | $15.00 | $15.00 |
| Christopher Raymond | Piper Sandler | Maintains | Overweight | $15.00 | $15.00 |
| Yigal Nochomovitz | Citigroup | Raises | Buy | $14.00 | $13.00 |
| Laura Chico | Wedbush | Raises | Outperform | $15.00 | $14.00 |
| Laura Chico | Wedbush | Raises | Outperform | $14.00 | $13.00 |
| Roanna Ruiz | Leerink Partners | Announces | Outperform | $14.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ardelyx. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Ardelyx compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ardelyx's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ardelyx's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Ardelyx analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Ardelyx
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Ardelyx: Financial Performance Dissected
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Ardelyx displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 304.81%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -57.62%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ardelyx's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -16.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Ardelyx's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -8.29%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Ardelyx's debt-to-equity ratio stands notably higher than the industry average, reaching 0.7. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Core of Analyst Ratings: What Every Investor Should Know
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
